EVA Pharma plans to make insulin locally for low- and middle-income classes
In collaboration with the American pharmaceutical corporation Elli Lilly, the Egyptian pharmaceutical company EVA Pharma plans to make insulin locally for low- and middle-income nations. The production will start to be distributed in 2024 and is expected to annually reach 1 million people in Africa.
Eli Lilly will give EVA Pharma the technology and active pharmaceutical ingredient (API) needed to manufacture the medication locally in accordance with international standards.
The beginning of a regional insulin production line through Egypt’s Medical Union Pharmaceutical Company, which would also export the medication throughout Africa, was earlier announced by the Ministry of Health and Population.
